journal
https://read.qxmd.com/read/37985430/mitocur-1-induces-ferroptosis-to-reverse-vemurafenib-resistance-in-melanoma-through-inhibition-of-usp14
#21
JOURNAL ARTICLE
Gege Li, Changlong Zhou, Lu Wang, Yalong Zheng, Bo Zhou, Guoyan Li, Zhongyu Ma, Peng Sun, Yuantao Deng, Li Su, Junling Wang, Hongmei Cui
Melanoma is an aggressive malignant tumor with a poor prognosis. Vemurafenib (PLX4032, vem) is applied to specifically treat BRAF V600E-mutated melanoma patients. However, prolonged usage of vem makes patients resistant to the drug and finally leads to clinical failure. We previously tested the combination regimen of tubulin inhibitor VERU-111 with vem, as well as USP14 selective inhibitor b-AP15 in combination with vem, both of which have showed profound therapeutic effects in overcoming vem resistance in vitro and in vivo...
November 20, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37975535/cd52-mrna-expression-predicts-prognosis-and-response-to-immune-checkpoint-blockade-in-melanoma
#22
JOURNAL ARTICLE
Luka de Vos-Hillebrand, Simon Fietz, Philip Hillebrand, Zsófi Kulcsár, Marie Yatou Diop, Sarah Hollick, Alexander Philippe Maas, Sebastian Strieth, Jennifer Landsberg, Dimo Dietrich
The immune-modulating protein CD52 attenuates lymphocyte function and is associated with autoimmune disorders, for example, multiple sclerosis (MS). CD52 represents a therapeutic target in MS and chronic lymphocytic leukemia (CLL). Its expression has prognostic and predictive value in CLL and is prognostic in breast cancer. Its significance in melanoma is unclear. We analyzed CD52 mRNA expression data from tumor bulk tissues of N = 445 untreated melanoma patients from The Cancer Genome Atlas (TCGA) Research Network and of N = 121 melanoma patients undergoing anti-PD-1 immune checkpoint blockade (ICB) with regard to outcome (overall survival [OS], disease control [DC], and progression-free survival [PFS]), single-cell RNA-Seq data of N = 4645 cells from N = 19 melanoma tissues, and N = 15,457 cells from normal skin provided by N = 5 donors...
November 17, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37972124/single-cell-profiling-of-mc1r-inhibited-melanocytes
#23
JOURNAL ARTICLE
H Matthew Berns, Dawn E Watkins-Chow, Sizhu Lu, Pakavarin Louphrasitthiphol, Tongwu Zhang, Kevin M Brown, Pedro Moura-Alves, Colin R Goding, William J Pavan
The human red hair color (RHC) trait is caused by increased pheomelanin (red-yellow) and reduced eumelanin (black-brown) pigment in skin and hair due to diminished melanocortin 1 receptor (MC1R) function. In addition, individuals harboring the RHC trait are predisposed to melanoma development. While MC1R variants have been established as causative of RHC and are a well-defined risk factor for melanoma, it remains unclear mechanistically why decreased MC1R signaling alters pigmentation and increases melanoma susceptibility...
November 16, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37953065/tfe3-promotes-ferroptosis-in-melanoma
#24
LETTER
Diogo Dias, Pakavarin Louphrasitthiphol, Colin R Goding
No abstract text is available yet for this article.
November 12, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37920136/cytoglobin-functions-as-a-redox-regulator-of-melanogenesis-in-normal-epidermal-melanocytes
#25
JOURNAL ARTICLE
Yo Tanaka, Misako Sato-Matsubara, Daisuke Tsuruta, Hiroshi Tanaka, Chiho Kadono, Koji Sugawara, Norifumi Kawada, Kazumasa Wakamatsu, Shosuke Ito, Katsutoshi Yoshizato
Epidermal melanocytes are continuously exposed to sunlight-induced reactive oxygen species (ROS) and oxidative stress generated during the synthesis of melanin. Therefore, they have developed mechanisms that maintain normal redox homeostasis. Cytoglobin (CYGB), a ubiquitously expressed intracellular iron hexacoordinated globin, exhibits antioxidant activity and regulates the redox state of mammalian cells through its activities as peroxidase and nitric oxide (NO) dioxygenase. We postulated that CYGB functions in the melanogenic process as a regulator that maintains oxidative stress within a physiological level...
November 2, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37917143/ipcc2023-looking-for-translational-opportunities-by-persevering-in-basic-pigment-cell-research
#26
JOURNAL ARTICLE
María D Boyano, Aintzane Asumendi, José Carlos Garcia-Borrón, Lluís Montoliu, Santos Alonso
No abstract text is available yet for this article.
November 2, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37903736/list-of-reviewers-for-pcmr-01-01-2023-30-09-2023
#27
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37903735/20th-anniversary-of-the-society-for-melanoma-research-celebrating-two-decades-of-progress-in-melanoma-research
#28
EDITORIAL
Ravi Amaravadi, Andrew Aplin, Meenhard Herlyn, Sheri Holmen, Richard White, Jessie Villanueva
No abstract text is available yet for this article.
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37903734/epilogue
#29
EDITORIAL
Vijayasaradhi Setaluri, Evan P And Marion Helfaer
No abstract text is available yet for this article.
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37903733/neutrophil-to-eosinophil-ratio-as-a-biomarker-for-clinical-outcomes-in-advanced-stage-melanoma-patients-treated-with-anti-pd-1-therapy
#30
JOURNAL ARTICLE
Vincent Pozorski, Yeonhee Park, Yusuf Mohamoud, Dahlia Tesfamichael, Hamid Emamekhoo, Alexander Birbrair, Mark R Albertini, Vincent T Ma
Neutrophil-to-lymphocyte ratios (NLR) and eosinophil counts are associated with improved survival in melanoma patients treated with immune checkpoint inhibitors, but no study has investigated neutrophil-to-eosinophil ratios (NER) as a predictive indicator in this population. In this retrospective study evaluating anti-PD-1 treated patients with advanced melanoma, progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and risk of high-grade (grade ≥3) immune-related adverse events (irAEs) were compared between groups defined by median pretreatment NLR and NER as well as median NLR and NER at 1-month post-treatment...
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37819777/progress-in-melanoma-treatment-patient-s-perspectives
#31
JOURNAL ARTICLE
Gretchen M Alicea, Jessie Villanueva, Marie R Webster, Vito W Rebecca
Upon the 20th Anniversary of the Society for Melanoma Research, we highlight the perspectives of patients aiming to help improve future experiences, outcomes, and their quality of life over the next 20 years. Five melanoma patients generously shared their inspiring and enlightening stories of diagnosis, treatment, and outcomes. Many patients had excellent medical teams that synergistically worked together to provide an accurate diagnosis, effective treatment options, and supportive care. However, it is clear that health inequities persist in communities where people of color are predominant, affecting early detection, patient experience, and outcomes...
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37770281/a-twenty-year-perspective-on-melanoma-therapy
#32
REVIEW
Keith T Flaherty
Melanoma had long been considered to be particularly addressable with immunotherapy, but that reputation was built on modestly effective cytokine-based immunotherapy. CTLA-4 antibody therapy reinforced this legacy, but PD-1 antibodies transformed the melanoma treatment landscape and lead the way for immunotherapy to become standard treatment for more than half of the advanced cancer population. BRAF mutations were discovered in 8% of all cancer and nearly 50% of melanomas. Successful development of BRAF inhibitors and BRAF/MEK combination therapy in melanoma preceded regulatory approval across all cancer types...
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37759408/brief-history-of-the-society-for-melanoma-research-a-community-of-clinicians-researchers-and-friends
#33
JOURNAL ARTICLE
Vito W Rebecca, Jessie Villanueva, Marie R Webster
To commemorate the 20th Anniversary of the Society of Melanoma Research and the first International Melanoma Research Congress held in June of 2003, we have described in brief, how the Society for Melanoma Research (SMR) began, the purpose, goals, and governance of the SMR, and how the society has evolved to support new melanoma researchers. In celebration of the immense progress in treating melanoma patients over the last 20 years and the impact of the SMR on these advances, we have highlighted memories and insight from early SMR members and founders...
November 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37886794/clinicopathological-features-current-status-and-progress-of-primary-central-nervous-system-melanoma-diagnosis-and-treatment
#34
REVIEW
Pengna Guo, Xiaoting Wei, Zhen Guo, Di Wu
Primary central nervous system (CNS) melanoma is an extremely rare condition, with an incidence rate of 0.01 per 100,000 individuals per year. Despite its rarity, the etiology and pathogenesis of this disease are not yet fully understood. Primary CNS melanoma exhibits highly aggressive biological behavior and presents clinically in a distinct manner from other types of melanomas. It can develop at any age, predominantly affecting the meninges as the primary site, with clinical symptoms varying depending on the neoplasm's location...
October 27, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37874775/the-mfsd12-p-tyr182his-common-variant-is-sufficient-to-alter-mouse-agouti-coat-color
#35
JOURNAL ARTICLE
Dawn E Watkins-Chow, Arturo A Incao, Cecelia Rivas, Gene Elliott, Lisa J Garrett, William J Pavan
MFSD12 functions as a transmembrane protein required for import of cysteine into melanosomes and lysosomes. The MFSD12 locus has been associated with phenotypic variation in skin color across African, Latin American, and East Asian populations. The frequency of a particular MFSD12 coding variant, rs2240751 (MAF = 0.08), has been reported to correlate with solar radiation and occur at highest frequency in Peruvian (PEL MAF = 0.48) and Han Chinese (CHB MAF = 0.40) populations, suggesting it could be causative for associated phenotypic variation in skin color...
October 24, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37819763/next-generation-of-melanoma-researchers-trainee%C3%A2-perspectives-from-around-the-world
#36
JOURNAL ARTICLE
Marie R Webster, Roderick Brathwaite, Jeremy A Bravo Narula, Vissy E Elad, Yanni Ma, Mei Fong Ng, Manoel Oliveira de Moraes Junior, Majahonkhe Shabangu, Christina Tsiavou, Jessie Villanueva, Vito W Rebecca
The Society for Melanoma Research (SMR) was created 20 years ago and has unequivocally contributed to the vast progress of the field, particularly for the treatment of melanoma patients with metastatic disease by facilitating synergistic collaborations between clinicians, researchers at the bench, and industry. In commemoration of the 20th anniversary of the first SMR International Congress (held in 2003 in Philadelphia), we look to the future by highlighting the perspectives of the next generation of rising stars, medical, and graduate students across six continents...
October 11, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37804122/proceedings-from-the-melanoma-research-foundation-mucosal-melanoma-meeting-december-16-2022-new-york-usa
#37
JOURNAL ARTICLE
Alexander Z Wei, Lanyi N Chen, Marlana Orloff, Charlotte E Ariyan, Maryam Asgari, Christopher A Barker, Elizabeth Buchbinder, Sunandana Chandra, Kasey Couts, Michael M Frumovitz, Andrew Futreal, Jeffrey E Gershenwald, Ehab Y Hanna, Benjamin Izar, Amy K LeBlanc, Mario M Leitao, Evan J Lipson, David Liu, Martin McCarter, Jennifer L McQuade, Yana Najjar, Suthee Rapisuwon, Sara Selig, Alexander N Shoushtari, Iwei Yeh, Gary K Schwartz, Jun Guo, Sapna P Patel, Richard D Carvajal
Mucosal melanoma remains a rare cancer with high mortality and a paucity of therapeutic options. This is due in significant part to its low incidence leading to limited patient access to expert care and downstream clinical/basic science data for research interrogation. Clinical challenges such as delayed and at times inaccurate diagnoses, and lack of consensus tumor staging have added to the suboptimal outcomes for these patients. Clinical trials, while promising, have been difficult to activate and accrue...
October 7, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37777339/nrf2-protein-in-melanoma-progression-as-a-new-means-of-treatment
#38
REVIEW
Qun Feng, Xiaolin Xu, Shoulin Zhang
Melanoma is a potentially lethal form of skin cancer resulting from the unlimited proliferation of melanocytes. Melanocytic lineage appears to have a greater rate of reactive oxygen species (ROS) production, possibly as a result of exposure to ultraviolet (UV) light and the production of melanin. It has been established that nuclear factor erythroid 2-related factor 2 (Nrf2) serves as a master regulator of the cellular response to oxidative stresses. Recent research has shown that the Nrf2 and its critical negative regulator Kelch-like ECH-associated protein 1 (Keap1) are misregulated in melanoma, and the Keap1-Nrf2 pathway has emerged as a promising new target for treating and preventing melanoma...
September 30, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37776566/laser-capture-microdissection-provides-a-novel-molecular-profile-of-human-primary-cutaneous-melanoma
#39
JOURNAL ARTICLE
Kristina Navrazhina, Sandra Garcet, Samuel C Williams, Nicholas Gulati, Felix Kiecker, John W Frew, Hiroshi Mitsui, James G Krueger
Melanoma accounts for the majority of skin cancer-related mortality, highlighting the need to better understand melanoma initiation and progression. In-depth molecular analysis of neoplastic melanocytes in whole tissue biopsies may be diluted by inflammatory infiltration, which may obscure gene signatures specific to neoplastic cells. Thus, a method is needed to precisely uncover molecular changes specific to tumor cells from a limited sample of primary melanomas. Here, we performed laser capture microdissection (LCM) and gene expression profiling of patient-derived frozen sections of pigmented lesions and primary cutaneous melanoma...
September 30, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37758515/anti-melanogenic-effect-of-exosomes-derived-from-human-dermal-fibroblasts-bj-5ta-ex-in-c57bl-6-mice-and-b16f10-melanoma-cells
#40
JOURNAL ARTICLE
Jung Min Lee, Jung Ok Lee, Yujin Kim, You Na Jang, A Yeon Park, Su-Young Kim, Hye Sung Han, Beom Joon Kim, Kwang Ho Yoo
Exosomes are involved in intercellular communication by transferring cargo between cells and altering the specific functions of the target cells. Recent studies have demonstrated the therapeutic effects of exosomes in several skin diseases. However, understanding of the effects of exosomes on anti-pigmentation is limited. Therefore, we investigated whether BJ-5ta exosomes (BJ-5ta-Ex) derived from human foreskin fibroblasts regulate melanogenesis and delineated the underlying mechanism. Interestingly, treatment with BJ-5ta-Ex induced decreased melanin content, tyrosinase (TYR) activity, and expression of melanogenesis-related genes, including microphthalmia-related transcription factor (MITF), TYR, tyrosinase-related protein-1 (TRP1), and tyrosinase-related protein-2 (TRP2)...
September 27, 2023: Pigment Cell & Melanoma Research
journal
journal
41776
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.